CSBio CSBio

X
[{"orgOrder":0,"company":"Flamma SpA","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Flamma, Gilead Continue Mfg. Partnership for Veklury","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Flamma SpA"},{"orgOrder":0,"company":"Menarini","sponsor":"SciClone","pharmaFlowCategory":"D","amount":"$113.0 million","upfrontCash":"Undisclosed","newsHeadline":"Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem\u00ae in China to Treat Antimicrobial Resistant Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Menarini"},{"orgOrder":0,"company":"Lo.Li. Pharma International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pervistop\u00ae, The Once-daily Supplement Specifically Designed To Manage Persistent HPV, Is Now Available For Exclusive Distribution Rights Worldwide","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Lo.Li. Pharma International"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Pervistop (Epigallocatechin Gallate) once-daily supplement provides a true alternative to eradicating the root problem of HPV persistence, which can unpredictably evolve into cancer.

            Lead Product(s): Green Tea Extract,Hyaluronic Acid,Vitamin B12

            Therapeutic Area: Infections and Infectious Diseases Product Name: Pervistop

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the License Agreement, SciClone will be responsible for conducting and funding local clinical development as well as commercialization of Vaborem® (meropenem). To facilitate patients in China, SciClone will conduct local clinical trials and pursue approvals in China.

            Lead Product(s): Meropenem,Vaborbactam

            Therapeutic Area: Infections and Infectious Diseases Product Name: Vaborem

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: SciClone

            Deal Size: $113.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement September 20, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Flamma has entered into an agreement with Gilead earlier this year to be part of the network of manufacturers contributing to the Veklury® supply chain. Flamma will continue to use its sites in Italy and China to support Gilead in supplies of the drug for Covid-19.

            Lead Product(s): Remdesivir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Veklury

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Gilead Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership November 05, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY